Study design and participants
DISEASE
This was an investigator‐initiated nonrandomized phase 2 clinical trial of palbociclib and ganitumab in patients with relapsed or refractory EWS (NCT04129151). This study was conducted at a single center including pediatric and adult patients.Participants were initially required to be ≥12 years and ≤ 50 years of age at study entry, and later any age ≥ 12 years following study amendment. A Karnofsky performance status of ≥50% for patients ≥16 years of age and Lansky performance status of ≥50% for participants <16 years of age was required. All participants were required to have RECIST v1.1 measurable disease.